Clinical Trial

Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation

Study acronym: ATRACTion
Recruiting
View on ClinicalTrials.gov →
Summary
The main objective of this study is to generate diagnosis and therapeutic-decision tools through the identification of molecular causes of PIDs with autoimmunity/inflammation and the variability in disease outcome at the transcriptional level using a combination of omics signatures (transcriptomics, epigenomics, proteomics, metagenomics, metabolomics and lipidomics).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2021-05-21; most recent amendment 2025-09-02.
Status change: Not Yet Recruiting → Recruiting 2025-09-02
Trial Details
NCT Number NCT04902807
Lead Sponsor Institut National de la Santé Et de la Recherche Médicale, France
Conditions Autoimmune Lymphoproliferative Syndrome, Autoimmune Cytopenia, Autoimmune Diseases, Autoimmune Anemia, Autoimmune Thrombocytopenia, Autoimmune Hepatitis, Autoimmune Diabetes, Autoimmune Rheumatologic Disease +12 more
Enrollment 500 participants
Start Date 2021-09-07
Primary Completion 2025-05-14 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2025-09-08